Tuesday 21 November 2017

iVeena Delivery Systems Receives FDA Orphan Drug Designation for IVMED-80 for the Treatment of Keratoconus

A good news for all Keratoconus patients!!!
U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IVMED-80, for the treatment of keratoconus…!!!
iVeena Delivery Systems, Inc. (iVeena) is a biopharmaceutical company. It is known for developing innovative ophthalmology products.
IVMED-80 is the first non-surgical and non-laser treatment for the cross-linking of cornea.
IVMED-80 is an eye-drop that can be used for crosslinking of the cornea.
IVMED-80 strengthens the cornea biomechanically through the daily application of this eye-drop.
Its clinical development will begin in early 2018.
 “Receiving orphan drug designation is an important regulatory milestone, and we are pleased that IVMED-80 for keratoconus has been granted this status,” said Gerald Simmons, CEO of iVeena Delivery Systems. “We are developing IVMED-80 to offer another option in the treatment of keratoconus. The prospect of treating keratoconus with only a daily eye-drop is very attractive and our team is committed to advancing the clinical development.”


    I need your contribution in spreading awareness about keratoconus. So please SHARE it by clicking on the buttons just below....


    No comments:

    Post a Comment